Works matching IS 14642662 AND DT 2007 AND VI 8 AND IP 4

Results: 11

A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.

Published in:

2007

By:

Youle M;
Osio M;
ALCAR Study Group

Publication type:

Journal Article

Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.

Published in:

HIV Medicine, 2007, v. 8, n. 4, p. 259, doi. 10.1111/j.1468-1293.2007.00465.x

By:

Hill, A.;
Moyle, G.

Publication type:

Article

Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.

Published in:

HIV Medicine, 2007, v. 8, n. 4, p. 234, doi. 10.1111/j.1468-1293.2007.00466.x

By:

Hill, A.;
Montaner, J.;
Smith, C.

Publication type:

Article

A double-blind, parallel-group, placebo-controlled, multicentre study of acetyll-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.

Published in:

HIV Medicine, 2007, v. 8, n. 4, p. 241, doi. 10.1111/j.1468-1293.2007.00467.x

By:

Youle, M.;
Osio, M.

Publication type:

Article

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.

Published in:

2007

By:

Laurichesse J;
Persoz A;
Theodorou I;
Rouzioux C;
Delfraissy J;
Meyer L

Publication type:

Journal Article

Seroprevalence of HIV infection in hospitalized paediatric patients at a tertiary care centre in western India.

Published in:

2007

By:

Shah, I.;
Katira, B.

Publication type:

Letter

Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

Published in:

HIV Medicine, 2007, v. 8, n. 4, p. 226, doi. 10.1111/j.1468-1293.2007.00464.x

By:

Mallolas, J.;
Blanco, J. L.;
Labarga, P.;
Vergara, A.;
Ocampo, A.;
Sarasa, M.;
Arnedo, M.;
López-Púa, Y.;
García, J.;
Juega, J.;
Guelar, A.;
Terrón, A.;
Dalmau, D.;
García, I.;
Zárraga, M.;
Martínez, E.;
Carn, X.;
Pumarola, T.;
Escayola, R.;
Gatell, J. M.

Publication type:

Article

Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of life in a resource-poor setting.

Published in:

HIV Medicine, 2007, v. 8, n. 4, p. 203, doi. 10.1111/j.1468-1293.2007.00454.x

By:

Smith Fawzi, M. C.;
Kaaya, S. F.;
Mbwambo, J.;
Msamanga, G. I.;
Antelman, G.;
Wei, R.;
Hunter, D. J.;
Fawzi, W. W.

Publication type:

Article

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Δ32 deletion.

Published in:

HIV Medicine, 2007, v. 8, n. 4, p. 213, doi. 10.1111/j.1468-1293.2007.00455.x

By:

Laurichesse, J. J.;
Persoz, A.;
Theodorou, I.;
Rouzioux, C.;
Delfraissy, J. F.;
Meyer, L.

Publication type:

Article

Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.

Published in:

HIV Medicine, 2007, v. 8, n. 4, p. 220, doi. 10.1111/j.1468-1293.2007.00456.x

By:

van Lunzen, J.;
Liess, H.;
Arastéh, K.;
Walli, R.;
Daut, B.;
Schürmann, D.

Publication type:

Article

Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.

Published in:

HIV Medicine, 2007, v. 8, n. 4, p. 251, doi. 10.1111/j.1468-1293.2007.00468.x

By:

Martínez, E.;
Milinkovic, A.;
Buira, E.;
de Lazzari, E.;
León, A.;
Larrousse, M.;
Lonc, M.;
Laguno, M.;
Blanco, J. L.;
Mallolas, J.;
García, F.;
Mir, J. M.;
Gatell, J. M.

Publication type:

Article